Landmark Ideas Series: Dr. Rich Miner

Speaker: Rich Miner, PhD, at GV

Date: January 12, 2023 at 4:00PM - 5:30PM

Dr. Mandl and Dr. Miner will have a fireside chat.

Rich Miner has been helping to build innovative technologies and companies with global impact for almost 40 years. He is a co-founder of Android, the world's most popular operating system with over 3 billion active users. After selling Android to Google in 2005 and launching the first few releases Rich co-founded GV,  Google’s first venture fund. GV has led investments in a number of the past decades' most successful startups and Rich specifically backed some of Massachusetts top startups including Recorded Future, Toast, HubSpot and Tamr.

In the late 1980s, Rich helped incubate Avid Technology, creator of the first computer video editing platform, at U. Mass Lowell. Then in the early 1990s he co-founded Wildfire Communications, which developed the world’s first voice-based personal assistant,  patenting many of the concepts now common in today's voice assistants.  In April 2000, Wildfire was sold to Orange, where Rich served as vice president of innovation and led their R&D in North America. While at Orange, he also started their venture fund Orange Ventures which invested in Boston area startups like Netezza. 

Rich received his Ph.D., Master and B.S.  in computer science from the University of Massachusetts at Lowell. Based in the Boston area, he continues to do advanced product development at Google as well as advise GV. He is also building and investing in  innovative startups with his angel fund, ExVC.


Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD, Kinsella JP, Mandl KD, Raj JU, Sleeper LA, . Pulmonary Hypertension in Children with Down Syndrome: Results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics 2022.

Wang X, Zhang HG, Xiong X, Hong C, Weber GM, Brat GA, Bonzel CL, Luo Y, Duan R, Palmer NP, Hutch MR, Gutiérrez-Sacristán A, Bellazzi R, Chiovato L, Cho K, Dagliati A, Estiri H, García-Barrio N, Griffier R, Hanauer DA, Ho YL, Holmes JH, Keller MS, Klann MEng JG, L'Yi S, Lozano-Zahonero S, Maidlow SE, Makoudjou A, Malovini A, Moal B, Moore JH, Morris M, Mowery DL, Murphy SN, Neuraz A, Yuan Ngiam K, Omenn GS, Patel LP, Pedrera-Jiménez M, Prunotto A, Jebathilagam Samayamuthu M, Sanz Vidorreta FJ, Schriver ER, Schubert P, Serrano-Balazote P, South AM, Tan ALM, Tan BWL, Tibollo V, Tippmann P, Visweswaran S, Xia Z, Yuan W, Zöller D, Kohane IS, Avillach P, Guo Z, Cai T, . SurvMaximin: Robust federated approach to transporting survival risk prediction models. Journal of biomedical informatics 2022.

Torous J, Stern AD, Bourgeois FT. Regulatory considerations to keep pace with innovation in digital health products. NPJ digital medicine 2022.

Levy S, Wisk LE, Minegishi M, Ertman B, Lunstead J, Brogna M, Weitzman ER. Association of Screening and Brief Intervention With Substance Use in Massachusetts Middle and High Schools. JAMA network open 2022.

Nielsen M, Presti M, Sztupinszki Z, Jensen AWP, Draghi A, Chamberlain CA, Schina A, Yde CW, Wojcik J, Szallasi Z, Crowther MD, Svane IM, Donia M. Co-existing alterations of MHC class I antigen presentation and IFNγ signaling mediate acquired resistance of melanoma to post-PD-1 immunotherapy. Cancer immunology research 2022.